New method using imaging analysis for assisting with prognosis of dlbcl patients

The present invention relates to a method for assisting with lymphoma prognosis. The prognosis of therapeutic response of patients with lymphoma is difficult. Based on a study of advanced stage DLBCL patients, the inventors showed that medical imaging such as 18F-FDG-PET/CT can provide a prognostic radiomic signature combining metrics reflecting tumor dissemination and tumor burden. In another aspect, the invention relates to a computer software comprising instructions to implement at least a part of a method according to the invention. In yet another aspect, the invention relates to a computer-readable non-transient recording medium on which a software is registered to implement a method according to the invention.

Scientific publication(s):
J Nucl Med, 2020 Jan, Cottereau AS. Et al., 18F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of Outcome, doi: 10.2967/jnumed.119.229450

Keywords: Imaging, Treatment Response, Prognosis in Cancer, Non Hodgkin’s B cell Lymphoma, Diffuse large B-cell lymphoma, DLBCL
Patent Application number: European Procedure (Patents) (EPA) - 31 Mai 2019 - 19305697.5
Inventors:
BUVAT-GUILLEMET Irène,NIOCHE Christophe,COTTEREAU Anne-Ségolène,MEIGNAN Michel
Publications:
J Nucl Med. 2020 Jan;61(1):40-45. doi: 10.2967/jnumed.119.229450. Epub 2019 Jun 14.

Reference:

MECA19045-D1

Business Developper
contact
Inserm Transfert
Business Developer
Patent filling date: 31-05-2019
Rare disease: No
Second indication: No

You might also be interested in